CHAMPIONS ONCOLOGY, INC. CSBR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
5/9
Piotroski F — financial health
-7.27
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $56.9M | $4.7M | — | $7.0M | $3.8M |
| 2024 | $50.2M | -$7.3M | — | -$7.0M | -$1.9M |
| 2023 | $53.9M | -$5.3M | — | $1.1M | $4.6M |
| 2022 | $49.1M | $548,000 | — | $4.1M | $9.1M |
| 2021 | $41.0M | $362,000 | — | -$5.0M | $7.4M |
| 2020 | $32.1M | -$2.1M | — | $685,000 | $5.1M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.27 (distress)
- Working capital / assets -0.046
- Retained earnings / assets -2.47
- EBIT / assets 0.141
- Equity / liabilities 0.132
Source: SEC EDGAR filings · CIK 0000771856 · as of 2025-04-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.